Using 68Ga-PSMA PET/CT for the Assessment of Osseous Tumor Burden in mCRPC Patients Undergoing 223Ra-dichloride Injections
Latest Information Update: 08 Mar 2022
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Diagnostic use
- 04 Jan 2022 Status changed from not yet recruiting to recruiting.
- 17 Aug 2021 Planned End Date changed from 31 Jul 2023 to 31 Dec 2024.
- 17 Aug 2021 Planned primary completion date changed from 31 Jul 2023 to 31 Jul 2024.